Cargando…

Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis

BACKGROUND: Subcutaneous depot medroxyprogesterone acetate is an easy-to-use injectable contraceptive. A trained person can administer it, including women through self-injection. The objective of this systematic review and meta-analysis was to assess the effectiveness and safety of self-injection ve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nabhan, Ashraf, Elshafeey, Farida, Mehrain, Luna Marion, Kabra, Rita, Elshabrawy, Amal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502084/ https://www.ncbi.nlm.nih.gov/pubmed/34627229 http://dx.doi.org/10.1186/s12905-021-01495-y

Ejemplares similares

Implementation strategies to scale up self-administered depot medroxyprogesterone acetate subcutaneous injectable contraception: a scoping review
por: Aderoba, Adeniyi Kolade, et al.
Publicado: (2023)

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
por: Curtis, Kathryn M., et al.
Publicado: (2021)

A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection()()()
por: Cover, Jane, et al.
Publicado: (2017)

Patient’s experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19()()
por: Smith, Tiffany Joyce, et al.
Publicado: (2023)

An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA)()()
por: Katz, Micah, et al.
Publicado: (2020)

The potential for intramuscular depot medroxyprogesterone acetate as a self-bridging emergency contraceptive()
por: Schickler, Robyn, et al.
Publicado: (2020)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Adolescent and covert family planning users’ experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate
por: Burke, Holly M., et al.
Publicado: (2020)

Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector()
por: Liu, Jenny, et al.
Publicado: (2018)

Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries
por: Stout, Anna, et al.
Publicado: (2018)

A randomized crossover study to evaluate local tolerability following subcutaneous administration of a new depot medroxyprogesterone acetate contraceptive formulation()
por: Halpern, Vera, et al.
Publicado: (2023)

High-risk sexual behaviors while on depot medroxyprogesterone acetate as compared to oral contraception
por: Bartz, Deborah, et al.
Publicado: (2017)

Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
por: Odwe, George, et al.
Publicado: (2018)

Evaluating the feasibility and acceptability of self-injection of subcutaneous depot medroxyprogesterone acetate (DMPA) in Senegal: a prospective cohort study()()()
por: Cover, Jane, et al.
Publicado: (2017)

Health care provider and client experiences of counselling on depot medroxyprogesterone acetate subcutaneous (DMPA-SC) for self-injection in Malawi
por: Porter Erlank, Chelsey, et al.
Publicado: (2023)

Hypercalcemia after the Discontinuation of Medroxyprogesterone Acetate
por: Yuasa-Shibasaki, Erina, et al.
Publicado: (2017)

Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera
por: Halpern, Vera, et al.
Publicado: (2021)

Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial()()
por: Nanda, Kavita, et al.
Publicado: (2016)

Resilient and Accelerated Scale-Up of Subcutaneously Administered Depot–Medroxyprogesterone Acetate in Nigeria (RASuDiN): A Mid-Line Study in COVID-19 Era
por: Osinowo, Kehinde, et al.
Publicado: (2021)

A comparative study on satisfaction from hormonal contraceptives: depot medroxyprogesterone acetate (DMPA), Cyclofem and LD
por: Fathizadeh, Nahid, et al.
Publicado: (2011)

The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates Mycobacterium tuberculosis–Specific Host Immunity Through the Glucocorticoid Receptor
por: Tomasicchio, Michele, et al.
Publicado: (2019)

Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results
por: Okegbe, Tishina, et al.
Publicado: (2019)

The Injectable-Only Contraceptive Medroxyprogesterone Acetate, Unlike Norethisterone Acetate and Progesterone, Regulates Inflammatory Genes in Endocervical Cells via the Glucocorticoid Receptor
por: Govender, Yashini, et al.
Publicado: (2014)

What Distinguishes Women Who Choose to Self-Inject? A Prospective Cohort Study of Subcutaneous Depot Medroxyprogesterone Acetate Users in Ghana
por: Nai, Dela, et al.
Publicado: (2022)

Trends in subcutaneous depot medroxyprogesterone acetate (DMPA-SC) use in Burkina Faso, the Democratic Republic of Congo and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2019)

Erratum for: Odwe et al., Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) Injectable Contraception at Facility and Community Levels: Pilot Results From 4 Districts of Uganda
Publicado: (2019)

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer*
por: Bloom, H. J. G.
Publicado: (1971)

Inhibitory Effects of Medroxyprogesterone Acetate on Mouse Endometrial Carcinogenesis
por: Niwa, Kenji, et al.
Publicado: (1995)

Medroxyprogesterone Acetate Alters Mycobacterium Bovis BCG-Induced Cytokine Production in Peripheral Blood Mononuclear Cells of Contraceptive Users
por: Kleynhans, Léanie, et al.
Publicado: (2011)

Is the Injectable Contraceptive Depo-Medroxyprogesterone Acetate (DMPA-IM) Associated with an Increased Risk for HIV Acquisition? The Jury Is Still Out
por: Hapgood, Janet P.
Publicado: (2020)

Characteristics associated with use of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Burkina Faso, Democratic Republic of Congo, and Uganda
por: Anglewicz, Philip, et al.
Publicado: (2021)

The Progestin-Only Contraceptive Medroxyprogesterone Acetate, but Not Norethisterone Acetate, Enhances HIV-1 Vpr-Mediated Apoptosis in Human CD4(+) T Cells through the Glucocorticoid Receptor
por: Tomasicchio, Michele, et al.
Publicado: (2013)

Effect of medroxyprogesterone acetate on the response of the rat mammary gland to carcinogenesis.
por: Russo, I. H., et al.
Publicado: (1989)

Incidence of Galactorrhea in Young Women Using Depot-Medroxyprogesterone Acetate
por: Omar, Hatim A., et al.
Publicado: (2006)

The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques
por: Daly, Michele B., et al.
Publicado: (2020)

Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
por: Harmon, Quaker E., et al.
Publicado: (2022)

Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
por: Lam, Clarissa, et al.
Publicado: (2016)

Changes in Hematologic Parameters during Treatment with Medroxyprogesterone Acetate for Breast Cancer
por: Yamamoto, Hitoshi, et al.
Publicado: (1991)

The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrations
por: Ray, Roslyn M., et al.
Publicado: (2019)

Bone Mineral Density in Antiretroviral Therapy‐Naïve HIV‐1–Infected Young Adult ‐Women Using Depot Medroxyprogesterone Acetate or Nonhormonal Contraceptives in Uganda
por: Matovu, Flavia Kiweewa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rbarps50mdufqprciubdojdtia